Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Abeona Therapeutics (ABEO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 602,336
  • Shares Outstanding, K 40,290
  • Annual Sales, $ 890 K
  • Annual Income, $ -21,870 K
  • 36-Month Beta 2.26
  • Price/Sales 734.14
  • Price/Cash Flow 0.00
  • Price/Book 7.32

Price Performance

See More
Period Period Low Period High Performance
1-Month
7.97 +87.46%
on 08/23/17
17.90 -16.48%
on 09/18/17
+7.10 (+90.45%)
since 08/22/17
3-Month
5.35 +179.44%
on 06/23/17
17.90 -16.48%
on 09/18/17
+9.35 (+166.96%)
since 06/22/17
52-Week
4.05 +269.14%
on 12/21/16
17.90 -16.48%
on 09/18/17
+8.56 (+133.96%)
since 09/22/16

Most Recent Stories

More News
Abeona Therapeutics Announces Upcoming Conference Participation

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare genetic diseases, today announced the Company's...

ABEO : 14.95 (-7.72%)
Technical Snapshots for These Biotech Stocks -- ImmunoCellular Therapeutics, Protalix BioTherapeutics, Synthetic Biologics, and Abeona Therapeutics

If you want a Stock Review on IMUC, PLX, SYN, or ABEO then come over to http://dailystocktracker.com/register/ and sign up for your free customized report. For today, DailyStockTracker.com shifts focus...

IMUC : 0.35 (+6.06%)
ABEO : 14.95 (-7.72%)
SYN : 0.98 (+2.08%)
PLX : 0.56 (-4.92%)
4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid

Though the biotech industry is doing well, it's a good idea to avoid a few stocks in the industry which will not prove to be prudent additions to your portfolio.

URGN : 30.49 (+3.32%)
ABEO : 14.95 (-7.72%)
CLSD : 8.30 (+1.84%)
RETA : 31.75 (+0.41%)
NVS : 86.16 (+1.44%)
GILD : 83.27 (+0.79%)
RHHBY : 32.0200 (-0.06%)
KITE : 179.30 (-0.04%)
AMGN : 185.76 (-0.47%)
Here's Why These 3 Biotech Stocks Might Stop Rallying

The momentum in the biotech sector is likely to continue. However, it's a good idea to avoid a few stocks that will possibly lose their momentum soon despite significant gains year to date.

KERX : 6.95 (+0.43%)
ABEO : 14.95 (-7.72%)
JNJ : 131.39 (-0.27%)
JUNO : 45.14 (+8.46%)
Abeona Therapeutics (ABEO) Surges: Stock Moves 22.9% Higher

Abeona Therapeutics (ABEO) shares rose nearly 23% in the last trading session, amid huge volumes.

ABEO : 14.95 (-7.72%)
ALXN : 142.82 (-0.07%)
Abeona Therapeutics Receives FDA Breakthrough Therapy Designation for EB-101 Autologous Cell Therapy in Epidermolysis Bullosa

-- FDA recently guided Company to accelerate Phase 3 trial for EB-101 autologous cell therapy

ABEO : 14.95 (-7.72%)
Corporate News Blog - BioDelivery Sciences CEO Dr. Mark A. Sirgo to Retire at Year-End; Will Continue as Vice Chairman

Research Desk Line-up: Abeona Therapeutics Post Earnings Coverage

ABEO : 14.95 (-7.72%)
BDSI : 2.80 (unch)
Abeona Therapeutics to Host Gene Therapy R&D Day on October 11, 2017

Abeona Therapeutics Inc. (Nasdaq:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, today announced it will host its...

ABEO : 14.95 (-7.72%)
Abeona Therapeutics Reports Second Quarter 2017 Financial Results and Recent Business Highlights

Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel gene therapies for life-threatening rare diseases, announced financial results for...

ABEO : 14.95 (-7.72%)
Top Companies Receiving Orphan Drug Designation in 2017

LAS VEGAS, July 28, 2017 /PRNewswire/ --

CNAT : 5.38 (-2.71%)
ABEO : 14.95 (-7.72%)
PPCB : 0.2900 (-4.13%)
MNK : 34.83 (-0.09%)
EPZM : 16.95 (-9.36%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Abeona Therapeutics, Inc. is engaged in developing and delivering gene therapy and plasma-based products for rare diseases. Abeona Therapeutics Inc., formerly known as PlasmaTech Biopharmaceuticals, Inc., is based in Dallas, United States.

See More

Support & Resistance

2nd Resistance Point 16.45
1st Resistance Point 15.70
Last Price 14.95
1st Support Level 14.40
2nd Support Level 13.85

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.